Innovotech Inc. announced today that its subsidiary, Innovotech Labs Corporation, is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The support will be used to develop new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings, addressing changes in international regulatory standards and manufacturers’ needs regarding proliferation, biofilm formation, and translocation of microorganisms.
This initiative builds on foundational development started last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand Innovotech’s service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing. Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. Learn more at https://www.innovotech.ca.
The NRC IRAP funding underscores the importance of antimicrobial testing in reducing healthcare-associated infections, particularly those linked to medical devices. With regulatory bodies tightening requirements, Innovotech’s enhanced testing services will enable manufacturers to better assess biofilm formation and microbial translocation, critical factors in device safety. This development is expected to accelerate product approvals and improve patient outcomes by reducing infection risks.
The Company’s forward-looking statements note that actual results may differ materially due to various risks and uncertainties, including regulatory outcomes, changes in the value of the Canadian dollar, reliance on a small number of customers, and intellectual property protection. The Company undertakes no obligation to update forward-looking statements except as required by law.
